Portal de Periódicos da CAPES

Clenbuterol and Anabolic Steroids

1998; Lippincott Williams & Wilkins; Volume: 91; Issue: 8 Linguagem: Inglês

10.1097/00007611-199808000-00019

1541-8243

Daniel R. Goldstein, Thomas Dobbs, BARBARA KRULL, Vance J. Plumb,

Analytical Methods in Pharmaceuticals

During the last 10 years, several cases of myocardial infarction associated with anabolic steroid use have been reported. Postulated mechanisms to explain this association have included changes in lipid levels, the fibrinolytic system, and platelet aggregation. Clenbuterol is a beta 2-agonist with anabolic properties that has not been seen previously with myocardial infarction. We report a case of myocardial infarction in an otherwise healthy 26-year-old body-builder who recently used clenbuterol and anabolic steroids. In this case, synergistic effects of the two agents seem likely to have played a role in the infarct. The normal coronary arteriograms before any anticoagulant or thrombolytic therapy strongly suggest coronary spasm as the mechanism of the infarct.